None
Quote | Brooklyn ImmunoTherapeutics Inc. (NYSE:BTX)
Last: | $9.01 |
---|---|
Change Percent: | -6.34% |
Open: | $9.59 |
Close: | $9.01 |
High: | $9.6 |
Low: | $8.7 |
Volume: | 880,740 |
Last Trade Date Time: | 10/22/2021 04:57:58 pm |
News | Brooklyn ImmunoTherapeutics Inc. (NYSE:BTX)
Brooklyn ImmunoTherapeutics ( NASDAQ: BTX ) said on Tuesday that it was changing its name to Eterna Therapeutics Inc. to reflect its focus on developing therapies using its patented in-licensed mRNA cell engineering technologies. The name change will be effec...
New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Company’s...
Message Board Posts | Brooklyn ImmunoTherapeutics Inc. (NYSE:BTX)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Brooklyn ImmunoTherapeutics Inc. Company Name:
BTX Stock Symbol:
NYSE Market:
Brooklyn ImmunoTherapeutics Inc. Website:
New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Company’s...
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnos...
SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology, today ann...